Results 131 to 140 of about 4,565 (192)

Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. [PDF]

J Manag Care Spec Pharm
Mudumba R, Liu X, Davis I, Romley JA, Nieva JJ.   +4 more
europepmc   +1 more source

Therapeutic Strategies to Overcome ALK Resistance in Cancer [PDF]

, 2021
A. Vv., A, Novello, S.
core  

A real-world pharmacovigilance analysis of ALK inhibitor-associated pleural and pericardial effusion using the FDA Adverse Events Reporting System (FAERS) database from 2013 to 2024. [PDF]

PLoS One
Frey C.
europepmc   +1 more source

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies [PDF]

, 2020
Ferrari, Katia, Roviello, Giandomenico, Traversini, Mirko, Voltolini, Luca   +3 more
core   +1 more source

Navigating treatment sequencing in ALK-positive non-small cell lung cancer: lorlatinib as a key to prolonged survival? [PDF]

Transl Lung Cancer Res
Ulhøi MP, Meldgaard P.
europepmc   +1 more source

Multidisciplinary treatment of advanced or metastatic ALK-positive non-small cell lung cancer: Real-world data on Brigatinib combined with local therapy. [PDF]

Medicine (Baltimore)
Illini O, Fabikan H, Breitenecker K, Lang-Stöberl AS, Krainer J, Krenbek D, Weinlinger C, Watzka S, Valipour A, Hochmair MJ.   +9 more
europepmc   +1 more source

Computational study of chalcone-cyanopyrimidine hybrids as LSD1 inhibitors: Assessing the influence of FAD on binding affinity and inhibition. [PDF]

Biochem Biophys Rep
Saifullah MK, Gupta A, Parveen D, Azam F, Alam MM, Akhter M, Parvez S, Maksud N, Azeez N, Shaquiquzzaman M.   +9 more
europepmc   +1 more source

Short‑term efficacy assessment of brigatinib for the treatment of neurofibromatosis type 2: A retrospective study. [PDF]

Oncol Lett
Lin Z, Yu W, Jing F, Xu Z, Liu M, Jiao S.   +5 more
europepmc   +1 more source

Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data. [PDF]

Front Oncol
Damuzzo V, Gasperoni L, Del Bono L, Ossato A, Inno A, Messori A.   +5 more
europepmc   +1 more source

Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study. [PDF]

Target Oncol
Mourlanette J, Rousseau-Bussac G, Mallah S, Guisier F, Zalcman G, Veillon R, Audigier-Valette C, Roa M, Nicolle I, Doubre H, Cloarec N, Lamy R, Morel H, Curcio H, Lagrange A, Schott R, Sabatini M, Toffart AC, Pinsolle J, Bennouna J, Chouaid C, Mazieres J.   +21 more
europepmc   +1 more source